These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 33434185)

  • 41. miR-654-5p Targets GRAP to Promote Proliferation, Metastasis, and Chemoresistance of Oral Squamous Cell Carcinoma Through Ras/MAPK Signaling.
    Lu M; Wang C; Chen W; Mao C; Wang J
    DNA Cell Biol; 2018 Apr; 37(4):381-388. PubMed ID: 29364705
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
    Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
    J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long non-coding RNA LINC00337 induces autophagy and chemoresistance to cisplatin in esophageal squamous cell carcinoma cells via upregulation of TPX2 by recruiting E2F4.
    Yang C; Shen S; Zheng X; Ye K; Ge H; Sun Y; Lu Y
    FASEB J; 2020 May; 34(5):6055-6069. PubMed ID: 32239565
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potential therapeutic effect of targeting glycogen synthase kinase 3β in esophageal squamous cell carcinoma.
    Bolidong D; Domoto T; Uehara M; Sabit H; Okumura T; Endo Y; Nakada M; Ninomiya I; Miyashita T; Wong RW; Minamoto T
    Sci Rep; 2020 Jul; 10(1):11807. PubMed ID: 32678196
    [TBL] [Abstract][Full Text] [Related]  

  • 45. METTL3/14 and IL-17 signaling contribute to CEBPA-DT enhanced oral cancer cisplatin resistance.
    Qiao X; Zhu L; Song R; Shang C; Guo Y
    Oral Dis; 2023 Apr; 29(3):942-956. PubMed ID: 34807506
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reversal of cisplatin resistance in oral squamous cell carcinoma by piperlongumine loaded smart nanoparticles through inhibition of Hippo-YAP signaling pathway.
    Sa P; Singh P; Panda S; Swain RK; Dash R; Sahoo SK
    Transl Res; 2024 Jun; 268():63-78. PubMed ID: 38499286
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
    Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
    Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models.
    Sobral LM; Sousa LO; Coletta RD; Cabral H; Greene LJ; Tajara EH; Gutkind JS; Curti C; Leopoldino AM
    Mol Cancer; 2014 Feb; 13():32. PubMed ID: 24555657
    [TBL] [Abstract][Full Text] [Related]  

  • 49. pERK-mediated IL8 secretion can enhance the migration, invasion, and cisplatin resistance of CD10-positive oral cancer cells.
    Pu Y; Li Q; Wang Y; Xu L; Qiao Q; Guo Y; Guo C
    BMC Cancer; 2021 Dec; 21(1):1283. PubMed ID: 34847866
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cisplatin-induced programmed cell death ligand-2 expression is associated with metastasis ability in oral squamous cell carcinoma.
    Sudo S; Kajiya H; Okano S; Sasaki M; Katsumata Y; Ohno J; Ikebe T; Hiraki A; Okabe K
    Cancer Sci; 2020 Apr; 111(4):1113-1123. PubMed ID: 32012401
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PSMC2 knockdown inhibits the progression of oral squamous cell carcinoma by promoting apoptosis via PI3K/Akt pathway.
    Wang Z; Xiong H; Zuo Y; Hu S; Zhu C; Min A
    Cell Cycle; 2022 Mar; 21(5):477-488. PubMed ID: 34979867
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential.
    Zhao L; Ren Y; Tang H; Wang W; He Q; Sun J; Zhou X; Wang A
    Oncotarget; 2015 Dec; 6(42):44538-50. PubMed ID: 26517090
    [TBL] [Abstract][Full Text] [Related]  

  • 53. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
    Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Isoliquiritigenin Inhibits Oral Squamous Cell Carcinoma and Overcomes Chemoresistance by Destruction of Survivin.
    Zhou Z; Han S; Liao J; Wang R; Yu X; Li M
    Am J Chin Med; 2023; 51(8):2221-2241. PubMed ID: 37930332
    [TBL] [Abstract][Full Text] [Related]  

  • 55. circPARD3 drives malignant progression and chemoresistance of laryngeal squamous cell carcinoma by inhibiting autophagy through the PRKCI-Akt-mTOR pathway.
    Gao W; Guo H; Niu M; Zheng X; Zhang Y; Xue X; Bo Y; Guan X; Li Z; Guo Y; He L; Zhang Y; Li L; Cao J; Wu Y
    Mol Cancer; 2020 Nov; 19(1):166. PubMed ID: 33234130
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel lncRNA LOLA1 may predict malignant progression and promote migration, invasion, and EMT of oral leukoplakia via the AKT/GSK-3β pathway.
    Liu W; Yao Y; Shi L; Tang G; Wu L
    J Cell Biochem; 2021 Oct; 122(10):1302-1312. PubMed ID: 33969929
    [TBL] [Abstract][Full Text] [Related]  

  • 57. C-reactive protein promotes tongue squamous cell carcinoma chemoresistance by inhibiting the activation of caspase-3/9 via the CD64/AKT/mTOR pathway.
    Yan X; Cao M; Wang Z; Wang S; Chen Q
    Hum Cell; 2021 Sep; 34(5):1424-1433. PubMed ID: 34019244
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Galectin‑3 blockade suppresses the growth of cetuximab‑resistant human oral squamous cell carcinoma.
    Yin P; Cui S; Liao X; Yao X
    Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328195
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of RIPK1 and FADD are associated with chemosensitivity and survival in head and heck squamous cell carcinoma via tanshinone IIA-mediated modulation of the RIPK1-FADD-Caspase 8 complex.
    Shen B; Han W; Tan X; Gu KJ; Naseem DF; Zheng G; Li G; Lou J; Chen C
    Mol Carcinog; 2024 Jul; 63(7):1406-1416. PubMed ID: 38695620
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
    Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
    Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.